Related Experiment Video
Updated: Jan 30, 2026

Construction and Testing of Coin Cells of Lithium Ion Batteries
Published on: August 2, 2012
Identification of NEK3 and MOK as novel targets for lithium
Ana Bravo1,2, Héctor de Lucio2, Pedro A Sánchez-Murcia1
1Área de Farmacología, Departamento de Ciencias Biomédicas, Unidad Asociada al IQM-CSIC, Universidad de Alcalá, Alcalá de Henares, Spain.
Abstract:
Lithium ion, commonly used as the carbonate salt in the treatment of bipolar disorders, has been identified as an inhibitor of several kinases, including Glycogen Synthase Kinase-3β, for almost 20 years. However, both the exact mechanism of enzymatic inhibition and its apparent specificity for certain metalloenzymes are still a matter of debate. A data-driven hypothesis is presented that accounts for the specificity profile of kinase inhibition by lithium in terms of the presence of a unique protein environment in the magnesium-binding site. This hypothesis has been validated by the discovery of two novel potential targets for lithium, namely NEK3 and MOK, which are related to neuronal function.
Insights
Lithium ions inhibit kinases by interacting with the magnesium-binding site. This study identifies novel lithium targets, NEK3 and MOK, potentially impacting neuronal function and bipolar disorder treatments.
Area of Science:
- Biochemistry
- Neuropharmacology
- Enzymology
Background:
- Lithium carbonate is a standard treatment for bipolar disorders.
- Lithium ion is known to inhibit various kinases, notably Glycogen Synthase Kinase-3β (GSK-3β), for two decades.
- The precise mechanism and specificity of lithium's kinase inhibition remain incompletely understood.
Discussion:
- A novel hypothesis proposes lithium's kinase inhibition specificity arises from unique protein environments in magnesium-binding sites.
- This data-driven hypothesis offers a mechanistic explanation for observed inhibition patterns.
- The hypothesis addresses the long-standing questions regarding lithium's enzyme interactions.
Key Insights:
- Lithium's specificity for certain metalloenzymes is explained by unique magnesium-binding site protein environments.
- NEK3 and MOK kinases are identified as novel potential targets for lithium.
- These targets are implicated in neuronal function, suggesting new therapeutic avenues.
Outlook:
- Further research can explore the therapeutic potential of targeting NEK3 and MOK with lithium.
- This work may lead to the development of more specific lithium-based therapeutics.
- Investigating lithium's interaction with other metalloenzymes could reveal additional targets.
Related Concept Videos
Methods of Classification and Identification
Targeted Cancer Therapies
There are several types of targeted therapies against...
Peptide Identification Using Tandem Mass Spectrometry
This technique helps gather information regarding the protein from which the peptide was obtained and to study the peptides’ amino acid sequence. Identifying peptides from a complex mixture is an important component of the growing field of...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Batteries and Fuel Cells

